"Edoxaban versus Warfarin in Patients with Atrial Fibrillation"
NEJM
http://www.nejm.org/doi/full/10.1056/NEJMoa1310907
"CONCLUSIONS

Both once-daily regimens of edoxaban were noninferior to warfarin with respect to the prevention of stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes. (Funded by Daiichi Sankyo Pharma Development; ENGAGE AF-TIMI 48 ClinicalTrials.gov number,NCT00781391.)"